Clinical Trials Browser

Phase 1 × INDUSTRY × Immune Checkpoint Inhibitors × Clear all

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1 Terminated

212 enrolled

Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04417465 2025-09-25

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Phase 1 Completed

101 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT06063681 2025-06-08

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

25 enrolled

Neoplasm Metastasis, Recurrence

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT04625205 2025-04-06

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Phase 1 Terminated

22 enrolled

Dermatologic

Melanoma

NCT06026254 2024-11-18

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Phase 1 Active not recruiting

2 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Phase 1 Completed

18 enrolled

Tumor-Agnostic

Neoplasms

NCT02574533 2017-09-27

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Phase 1 Completed

2 enrolled

Dermatologic

Melanoma